These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9372064)

  • 41. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Measurements of red cell deformability and hydration reflect HbF and HbA
    Parrow NL; Tu H; Nichols J; Violet PC; Pittman CA; Fitzhugh C; Fleming RE; Mohandas N; Tisdale JF; Levine M
    Blood Cells Mol Dis; 2017 Jun; 65():41-50. PubMed ID: 28472705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sickle Cell Disease: A Primer for Primary Care Providers.
    Kimrey S; Saving KL
    Pediatr Ann; 2020 Jan; 49(1):e43-e49. PubMed ID: 31930422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of hydroxyurea in sickle cell disease.
    Halsey C; Roberts IA
    Br J Haematol; 2003 Jan; 120(2):177-86. PubMed ID: 12542474
    [No Abstract]   [Full Text] [Related]  

  • 45. Long-term use of hydroxyurea for sickle cell anemia.
    Hagar W
    JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424
    [No Abstract]   [Full Text] [Related]  

  • 46. Haemoglobin F modulation in childhood sickle cell disease.
    Trompeter S; Roberts I
    Br J Haematol; 2009 Feb; 144(3):308-16. PubMed ID: 19036119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment.
    Fertrin KY; Costa FF
    Expert Rev Hematol; 2010 Aug; 3(4):443-58. PubMed ID: 21083035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
    Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hydroxyurea and sickle cell disease: a chance for every patient.
    Weiner DL; Brugnara C
    JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739
    [No Abstract]   [Full Text] [Related]  

  • 51. Hydroxyurea, sickle cell disease and renal transplantation.
    Allen A; Scoble J; Snowden S; Hambley H; Bellingham A
    Nephron; 1997; 75(1):106-7. PubMed ID: 9031282
    [No Abstract]   [Full Text] [Related]  

  • 52. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sickle cell paths converge on hydroxyurea.
    Platt OS
    Nat Med; 1995 Apr; 1(4):307-8. PubMed ID: 7585059
    [No Abstract]   [Full Text] [Related]  

  • 54. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sickle cell disease.
    Yardumian A; Crawley C
    Clin Med (Lond); 2001; 1(6):441-6. PubMed ID: 11792081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gastrointestinal and hepatic complications of sickle cell disease.
    Ebert EC; Nagar M; Hagspiel KD
    Clin Gastroenterol Hepatol; 2010 Jun; 8(6):483-9; quiz e70. PubMed ID: 20215064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sickle cell disease.
    Ware RE; de Montalembert M; Tshilolo L; Abboud MR
    Lancet; 2017 Jul; 390(10091):311-323. PubMed ID: 28159390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of anti-sickling effects of two varieties of Cajanus cajan (L.) Huth on sickle cell beta thalassemia.
    Anorue EC; Joshua PE
    J Ethnopharmacol; 2024 Sep; 331():118280. PubMed ID: 38714239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neonatal Screening and the Clinical Outcome in Children with Sickle Cell Disease in Central India.
    Upadhye DS; Jain DL; Trivedi YL; Nadkarni AH; Ghosh K; Colah RB
    PLoS One; 2016; 11(1):e0147081. PubMed ID: 26785407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.